HK1207828A1 - Cell-derived viral vaccines with low levels of residual cell dna dna - Google Patents

Cell-derived viral vaccines with low levels of residual cell dna dna

Info

Publication number
HK1207828A1
HK1207828A1 HK15108523.2A HK15108523A HK1207828A1 HK 1207828 A1 HK1207828 A1 HK 1207828A1 HK 15108523 A HK15108523 A HK 15108523A HK 1207828 A1 HK1207828 A1 HK 1207828A1
Authority
HK
Hong Kong
Prior art keywords
dna
cell
cell culture
low levels
residual
Prior art date
Application number
HK15108523.2A
Other languages
Chinese (zh)
Inventor
Holger Kost
Jens-Peter Gregersen
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1207828(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of HK1207828A1 publication Critical patent/HK1207828A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ²-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
HK15108523.2A 2005-11-01 2015-09-01 Cell-derived viral vaccines with low levels of residual cell dna dna HK1207828A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01

Publications (1)

Publication Number Publication Date
HK1207828A1 true HK1207828A1 (en) 2016-02-12

Family

ID=37969762

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09107245.9A HK1129837A1 (en) 2005-11-01 2009-08-07 Cell-derived viral vaccines with low levels of residual cell dna - dna
HK15108523.2A HK1207828A1 (en) 2005-11-01 2015-09-01 Cell-derived viral vaccines with low levels of residual cell dna dna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK09107245.9A HK1129837A1 (en) 2005-11-01 2009-08-07 Cell-derived viral vaccines with low levels of residual cell dna - dna

Country Status (19)

Country Link
US (2) US10655108B2 (en)
EP (3) EP1951296B2 (en)
JP (5) JP5602366B2 (en)
KR (1) KR20080081254A (en)
CN (2) CN104474543A (en)
AT (1) ATE494906T1 (en)
AU (2) AU2006310171B2 (en)
CA (1) CA2627971A1 (en)
CY (1) CY1111378T1 (en)
DE (1) DE602006019629D1 (en)
DK (1) DK1951296T4 (en)
EA (1) EA014062B1 (en)
ES (2) ES2525518T3 (en)
HK (2) HK1129837A1 (en)
NZ (1) NZ567817A (en)
PL (2) PL1951296T5 (en)
PT (1) PT2301572E (en)
SI (1) SI1951296T2 (en)
WO (1) WO2007052163A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104474543A (en) * 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
KR20110110853A (en) 2006-01-27 2011-10-07 노파르티스 파르마 아게 Influenza vaccines containing hemagglutinin and matrix proteins
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
EA201070066A1 (en) * 2007-06-27 2010-06-30 Новартис Аг VACCINES AGAINST FLU WITH LOW CONTENT OF ADDITIVES
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
EP2361304A2 (en) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Novel method
DE102010018462A1 (en) 2009-04-27 2011-04-07 Novartis Ag Vaccines for protection against influenza
CN102597246B (en) 2009-05-21 2014-02-26 诺华股份有限公司 Reverse genetics using non-endogenous pol I promoters
EP2459722B1 (en) 2009-07-31 2017-09-06 Seqirus UK Limited Reverse genetics systems
CN102648003B (en) 2009-10-09 2016-01-13 儿童医疗中心有限公司 The whole-cell vaccines of selective splitting
CA2778332A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
CN102946727B (en) * 2010-05-06 2015-08-19 诺华有限公司 The organic peroxide compounds of bacteria inactivation rate
CA2800150C (en) 2010-05-21 2018-09-04 Novartis Ag Influenza virus reassortment method
AU2011262312B2 (en) 2010-06-01 2015-05-28 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
DK2575872T3 (en) 2010-06-01 2020-10-19 Seqirus Uk Ltd CONCENTRATION OF INFLUENZA VACCINE ANTIGENES WITHOUT FREEZE DRYING
EP2603234B1 (en) 2010-08-12 2017-06-28 Yisheng Biopharma Holdings Ltd. Method for reducing dna impurities in viral compositions
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
EP2678452B1 (en) 2011-02-25 2016-02-24 Novartis AG Exogenous internal positive control for virus detection
WO2013098655A2 (en) * 2011-11-03 2013-07-04 Sentinext Therapeutics Sdn Bhd Antigens and vaccines directed against human enteroviruses
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
JP2015526062A (en) 2012-06-04 2015-09-10 ノバルティス アーゲー Improved safety testing
WO2014086732A2 (en) 2012-12-03 2014-06-12 Novartis Ag Influenza virus reassortment
MX2015011529A (en) 2013-03-13 2016-02-05 Novartis Ag Influenza b virus reassortment.
US20140335116A1 (en) 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005130U1 (en) 2013-06-05 2013-09-10 Novartis Ag Influenza virus reassortment
DE202013005100U1 (en) 2013-06-05 2013-08-26 Novartis Ag Influenza virus reassortment
WO2014195920A2 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (en) 2013-09-23 2015-03-25 恩金生物有限公司 Influenza vaccine and therapy
CN104513317B (en) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 A kind of vaccine composition and its preparation method and application
JP6373376B2 (en) 2013-11-15 2018-08-15 ノバルティス アーゲー Removal of residual cell culture impurities
CN106661102B (en) * 2014-05-28 2021-01-26 财团法人卫生研究院 Viral particles as immunogens against enterovirus infection and their manufacture
JP2018524323A (en) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド Antigen matched influenza vaccine
EP3764098B1 (en) 2015-07-07 2022-11-16 Seqirus UK Limited Influenza potency assays
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
CN109652384B (en) * 2019-02-21 2021-10-26 昆明理工大学 Method for culturing hepatitis E virus in vitro
JP2023502650A (en) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド Methods for Producing Genetically Reassorted Influenza Viruses
EP4316515A4 (en) * 2021-03-30 2024-09-25 Denka Company Ltd Influenza vaccine
CN116407624B (en) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) Preparation method and application of bacterial sample particle vaccine for infectious bronchitis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (en) * 1974-01-14 1977-07-15 Sandoz Ag
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4140762A (en) * 1974-01-14 1979-02-20 Sandoz Ltd. Influenza sub-unit vaccine
ES2061500T5 (en) 1986-06-17 2003-05-16 Chiron Corp DIAGNOSIS AND VACCINES OF DELTA HEPATITIS, ITS PREPARATION AND USE.
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (en) 1989-09-20 1999-08-30 国立予防衛生研究所 Method for producing HA protein
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
JP3108480B2 (en) 1991-09-25 2000-11-13 松下電工株式会社 Interrupt processing method for multiplex transmission system
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
DE19612967A1 (en) 1996-04-01 1997-10-02 Behringwerke Ag Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process
DE19612966B4 (en) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK cells and methods of propagating influenza viruses
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1999062546A1 (en) * 1998-06-01 1999-12-09 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
JP2000230931A (en) 1998-12-07 2000-08-22 Katakura Industries Co Ltd Method for detecting antibody against influenza virus of domestic animal and kit used therein
TR200103018T2 (en) * 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline Additive compounds containing immunostimulatory oligonucleotide and saponin.
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
HUP0202846A3 (en) 1999-09-24 2003-12-29 Smithkline Beecham Biolog Intranasal influenza virus vaccine
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
WO2001041814A1 (en) 1999-12-08 2001-06-14 Crucell Holland B.V. Method of administering adenovirus
ATE473272T1 (en) 2000-03-03 2010-07-15 Chemo Sero Therapeut Res Inst CELL USABLE IN SERUM-FREE CULTURE, CULTURE SUSPENSION AND METHOD FOR VIRUS PRODUCTION AS A VACCINE USING THE CELL
FR2808803B1 (en) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech MODIFIED ES CELLS AND SPECIFIC GENE OF ES CELLS
GB0024089D0 (en) * 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US20040071734A1 (en) * 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
US20040096463A1 (en) 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
AU2002254558A1 (en) 2001-04-27 2002-11-11 Becton, Dickinson And Company Novel vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (en) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Replication of virus in cell cultures, useful for preparing vaccines and diagnostic reagents, where replication of cells and virus is simultaneous
DE10144906B4 (en) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Process for the large-scale production of vaccines
FR2836924B1 (en) 2002-03-08 2005-01-14 Vivalis AVIAN CELL LINES USEFUL FOR THE PRODUCTION OF INTEREST SUBSTANCES
DK1499348T3 (en) 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
AU2003299244A1 (en) 2002-12-20 2004-07-14 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
US20060257852A1 (en) * 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
BRPI0410702B1 (en) 2003-05-28 2022-04-12 Wisconsin Alumni Research Foundation Composition, methods for preparing an influenza virus and gene delivery vehicle, and viruses
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
DE602005015332D1 (en) 2004-02-23 2009-08-20 Crucell Holland Bv Method for cleaning viruses
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
EP1747268A1 (en) 2004-05-20 2007-01-31 ID Biomedical Corporation Process for the production of an influenza vaccine
WO2006027698A1 (en) * 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Decreasing potential iatrogenic risks associated with influenza vaccines
JP4031478B2 (en) 2004-12-13 2008-01-09 プロテイン サイエンシーズ Method for producing influenza hemagglutinin multivalent vaccine
KR101323459B1 (en) 2004-12-23 2013-10-29 메디뮨 엘엘씨 Non-tumorigenic mdck cell line for propagating viruses
FR2884255B1 (en) 2005-04-11 2010-11-05 Vivalis USE OF EBX AVIATION STEM CELL LINES FOR THE PRODUCTION OF INFLUENZA VACCINE
CN104474543A (en) * 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
SG174813A1 (en) * 2006-09-15 2011-10-28 Medimmune Llc Mdck cell lines supporting viral growth to high titers and bioreactor process using the same

Also Published As

Publication number Publication date
BRPI0618094A2 (en) 2011-08-16
AU2011201968B2 (en) 2014-08-28
HK1129837A1 (en) 2009-12-11
WO2007052163A3 (en) 2007-09-07
US10655108B2 (en) 2020-05-19
JP2016185988A (en) 2016-10-27
AU2006310171B2 (en) 2011-02-17
DE602006019629D1 (en) 2011-02-24
JP6639077B2 (en) 2020-02-05
JP2014198726A (en) 2014-10-23
JP2011256209A (en) 2011-12-22
US20200377864A1 (en) 2020-12-03
AU2006310171A1 (en) 2007-05-10
US20090304729A1 (en) 2009-12-10
AU2011201968A1 (en) 2011-05-19
BRPI0618094A8 (en) 2017-08-22
CN104474543A (en) 2015-04-01
PL2301572T3 (en) 2015-02-27
NZ567817A (en) 2012-01-12
EP1951296A2 (en) 2008-08-06
ES2359214T5 (en) 2014-10-08
DK1951296T3 (en) 2011-03-28
EP2301572B1 (en) 2014-09-10
ES2359214T3 (en) 2011-05-19
SI1951296T1 (en) 2011-04-29
EA014062B1 (en) 2010-08-30
JP7049761B2 (en) 2022-04-07
KR20080081254A (en) 2008-09-09
CA2627971A1 (en) 2007-05-10
EP1951296B1 (en) 2011-01-12
JP2020023557A (en) 2020-02-13
ES2525518T3 (en) 2014-12-26
EP1951296B2 (en) 2014-07-23
JP5602366B2 (en) 2014-10-08
PL1951296T3 (en) 2011-09-30
PT2301572E (en) 2014-12-22
EA200801221A1 (en) 2008-10-30
CN101365480B (en) 2014-11-05
DK1951296T4 (en) 2014-09-01
US11466257B2 (en) 2022-10-11
WO2007052163A2 (en) 2007-05-10
CN101365480A (en) 2009-02-11
ATE494906T1 (en) 2011-01-15
PL1951296T5 (en) 2015-06-30
EP2842572A1 (en) 2015-03-04
CY1111378T1 (en) 2015-08-05
EP2301572A1 (en) 2011-03-30
JP2009513694A (en) 2009-04-02
SI1951296T2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
HK1207828A1 (en) Cell-derived viral vaccines with low levels of residual cell dna dna
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2007024941A3 (en) Polyvalent vaccine
BR112013011194A2 (en) rabies virus-like glycoprotein particles (vlps).
MX2012000035A (en) Recombinant rsv antigens.
EP4368202A3 (en) Attenuated viruses useful for vaccines
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2004112831A3 (en) High titer recombinant influenza viruses for vaccines and gene therapy
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
WO2007117303A3 (en) Combination vaccine comprising an attenuated bovine viral diarrhea virus
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2006074303A3 (en) Delivery vehicles, bioactive substances and viral vaccines
WO2011082388A3 (en) Infectious dna vaccines against chikungunya virus
WO2010001409A3 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
EA201170533A1 (en) HIGHLY PERFORMED SILICON DIOXIDE FOR RUBBER AND WAY TO OBTAIN
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2010095041A3 (en) Compositions, methods, and kits for treating influenza viral infections
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
PH12015501378B1 (en) Porcine parvovirus 5a, methods of use and vaccine
WO2009080715A3 (en) Vaccines for malaria
WO2008115314A3 (en) Flavivirus vaccine vector against influenza virus
WO2008124176A3 (en) Soluble and membrane-anchored forms of lassa virus subunit proteins
TW200531701A (en) Method of vaccination against testicular BVDV infection
WO2008002152A3 (en) Process for culturing bacteria of the piscirickettsia genus